Bayer finds itself at a critical juncture this week as two separate court hearings in the United States and a brewing political fight in Germany converge to shape the outlook for the pharmaceuticals and agriculture group. On one front, a federal judge in San Francisco is weighing the future of nearly 4,000 consolidated Roundup lawsuits, while on another, a state court is preparing to finalize a $7.25 billion settlement covering roughly 60,000 claims. Simultaneously, the German government is pushing through a healthcare savings bill that would impose new price caps and rebates on the drug industry.
At the federal level, Judge Vincent Chhabria convened a status conference Wednesday after postponing it from Tuesday to give both sides more time to explain the implications of the Supreme Court’s late June ruling. That decision held that Bayer cannot be sued over failure to include cancer warnings on Roundup labels because federal labeling requirements preempt state-level demands. But the judge was not satisfied with the initial submissions, calling them “unbefriedigend” (unsatisfactory) on Monday. Plaintiffs’ attorney Robin Greenwald argues that the Supreme Court’s ruling only applies to labeling, leaving intact claims based on defective design or negligence. Chhabria’s decision on whether to dismiss the entire multidistrict litigation or allow parts to proceed will be a major catalyst for the stock.
Separately, a class-action settlement worth $7.25 billion that aims to resolve Roundup claims at the state-court level is moving toward final approval. Judge Stephen Boyer of the Missouri Circuit Court has scheduled a hearing for August 19 to grant final certification. Bayer has endorsed this timeline. If approved, it would remove a significant chunk of the legal overhang that has weighed on the company for years.
Back in Germany, the political landscape is adding a new layer of uncertainty. The government plans to pass the GKV-Spargesetz (a healthcare savings law) on Friday, introducing drug price caps and mandatory discounts that would eat into profits of Bayer’s pharmaceutical division. Opposition parties have filed emergency motions with the Federal Constitutional Court in Karlsruhe seeking to block the parliamentary vote at short notice. A ruling from the court could indirectly cap the earnings potential of Bayer’s prescription drugs business just as investors are turning more optimistic about the legal front.
That optimism has been reflected in several analyst upgrades over recent days. Goldman Sachs raised its price target on Bayer from €55 to €62.50, reiterating a “Buy” rating as analyst James Quigley trimmed the discount applied to the pharmaceuticals business and lowered his cost-of-capital assumptions in light of reduced legal risks. Deutsche Bank went a step further, lifting its rating from “Hold” to “Buy” and boosting its target from €45 to €60. Berenberg also increased its target from €40.50 to €55 but kept its “Hold” rating unchanged, with analyst Sebastian Bray more cautious than his peers.
Should investors sell immediately? Or is it worth buying Bayer?
The overall consensus from 18 analysts stands at €51.92, with the range spanning €40.50 to €65.00. The average recommendation is “Outperform,” which sits marginally below the current share level — a subtle reminder that the stock has already priced in much of the good news.
Bayer shares closed Wednesday at €50.36, less than 7% below the 52-week high of €53.86 reached on July 3. Over the past month, the stock has surged 42.46%, and over twelve months the gain is a remarkable 84%. The rally has lifted the stock well above its 50-day moving average of €39.62, a 27% gap that underscores the speed of the advance. However, the relative strength index (RSI) has climbed to 72.4, firmly in overbought territory, while the stock’s volatility stands at nearly 65%, reflecting traders’ nervousness.
The strain showed last week when the stock shed 5.05%, a sign that some investors are taking profits after the steep climb. The technical overhang means the stock is vulnerable to a sharp pullback if the court hearings produce any negative surprises.
Looking ahead, the legal calendar dictates the near-term narrative. The outcome of Wednesday’s status conference with Judge Chhabria could either clear a major hurdle or prolong uncertainty. Then the August 19 hearing in Missouri will determine the fate of the $7.25 billion settlement. If both rulings break in Bayer’s favor, the path to a potential breakup — such as a partial IPO of the agriculture division — would become much clearer. Until then, the stock remains hostage to the interplay of courtroom decisions, political maneuvering, and technical exhaustion.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from July 9 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 9.
Bayer: Buy or sell? Read more here...
